Company intelligence / Profile preview

Molbio Diagnostics

Verna, Goa, India

Ownership: Private
Employees: ~590
Development stage: Other

Overview

Molbio's Truenat platform is WHO-endorsed for rapid, point-of-care real-time PCR diagnosis of tuberculosis (including rifampicin resistance) and has been validated and deployed for multiple infectious diseases including COVID-19, hepatitis, and more. It is commercially deployed in over 85 countries, with impact validated through national TB and pandemic response programs.[1][2][3][6]

Therapeutic areas: HematologyOncologyInfectious Diseases
Modalities: DeviceMolecular diagnostics platform
Industry: Molecular Diagnostics

Partnerships

World Health OrganizationIndian Council of Medical Research (ICMR)Find DiagnosticsState governments in IndiaGrand Challenges Canada

Beyond the preview

Go deeper on Molbio Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Molbio Diagnostics.

Explore the full profile